Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
920.69 -1.71 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Founded
1988
CEO
Dr. Leonard S. Schleifer,M.D.,PhD
Employees
15,410
Headquarters
Tarrytown, New York, United States of America
Fiscal year end
12-31
Website
regeneron.com

Company profile

Exchange
US
Symbol
REGN
Market-cap rank
#285
Listing date
1970-01-01
Market cap
95.24B
Float cap
91.57B
Shares out
103.45M
Float shares
99.46M

Sectors & themes

Biotechnology ARK Portfolio Infectious Disease Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Regeneron Pharmaceuticals discussion 0 comments

Add a comment